Nanoparticles have gained prominence in many areas and domains worldwide, such as metallic NP, carbon dots, quantum dots, polymeric NP, nano-suspension, nanocrystals, solid lipid nanoparticles (SLN), etc. and have been applied in the field of medicine as nanomedicine with promising results. Rise in cancer mortality rate has been an issue for a long time with female breast cancer as one of the most detected cancers. No permanent treatment has been developed till date could combat breast cancer with minimum side effects that are not long-lasting as there is no proper technique through which the anticancer drugs can recognize benign or malignant or normal cells that causes systematic toxicity. Advancement in technology has led to the discovery of many biological pathways and mechanisms. Tumor cells or cancer cells overexpress some high-affinity receptors that can be targeted to deliver the anticancer drugs at specific site using these pathways and mechanisms. Solid lipid nanoparticles (SLN) are among some of the excellent drug delivery systems, especially stealth SLN (sSLN). SLN, when conjugated with a ligand (called as sSLN), has affinity and specificity towards a specific receptor, and can deliver the drug in breast cancer cells overexpressing the receptors. Using this technique, various investigations have reported better anti-breast cancer activity than simple SLN (non-conjugated to ligand or no receptor targeting). This review includes the investigations and data on receptor-mediated targeting in breast cancer from 2010 to 2021 by searching different databases. Overall, information on SLN in different cancers is reviewed. In vivo investigations, pharmacokinetics, biodistribution, and stability are discussed to describe the efficacy of sSLN. Investigations included in this review demonstrate that sSLN delivers the drug by overcoming the biological barriers and shows enhanced and better activity than non-conjugated SLN which also verifies that a lesser concentration of drug can show anti-breast cancer activity. The efficacy of medicines could be increased with lower cancer deaths through stealth-SLN. Due to the low cost of synthesis, biocompatibility and easy to formulate, more study is needed in vitro and in vivo so that this novel technique could be utilized in the treatment of human breast cancer.

中文翻译：

---

固体脂质纳米颗粒在乳腺癌中的受体介导靶向作用及其机制。

纳米粒子在世界范围内的许多领域和领域都得到了突出的应用，如金属纳米粒子、碳点、量子点、聚合物纳米粒子、纳米悬浮液、纳米晶体、固体脂质纳米粒子（SLN）等，并在医学领域得到应用，如具有可喜成果的纳米医学。长期以来，癌症死亡率的上升一直是一个问题，女性乳腺癌是发现率最高的癌症之一。迄今为止，还没有开发出永久性的治疗方法可以以最小的副作用对抗乳腺癌，而且不会持久，因为没有适当的技术可以让抗癌药物识别良性或恶性或引起全身毒性的正常细胞。技术的进步导致许多生物学途径和机制的发现。肿瘤细胞或癌细胞过度表达一些高亲和力受体，可以使用这些途径和机制靶向在特定部位递送抗癌药物。固体脂质纳米颗粒 (SLN) 是一些优秀的药物输送系统之一，尤其是隐形 SLN (sSLN)。SLN 在与配体（称为 sSLN）缀合时，对特定受体具有亲和力和特异性，并且可以在过表达受体的乳腺癌细胞中递送药物。使用这种技术，各种研究报告了比简单的 SLN（未与配体结合或无受体靶向）更好的抗乳腺癌活性。本综述通过搜索不同的数据库，收录了 2010 年至 2021 年乳腺癌受体介导靶向的研究和数据。总体而言，回顾了不同癌症中 SLN 的信息。讨论体内研究、药代动力学、生物分布和稳定性以描述 sSLN 的功效。本综述中包含的调查表明，sSLN 通过克服生物屏障来递送药物，并显示出比未结合的 SLN 增强和更好的活性，这也证实了较低浓度的药物可以显示出抗乳腺癌活性。通过隐形 SLN，可以提高药物的疗效，降低癌症死亡率。由于合成成本低、生物相容性和易于配制，需要在体外​​和体内进行更多研究，以便将这种新技术用于治疗人类乳腺癌。本综述中的研究表明，sSLN 通过克服生物屏障来递送药物，并显示出比未结合的 SLN 增强和更好的活性，这也证实了较低浓度的药物可以显示出抗乳腺癌活性。通过隐形 SLN，可以提高药物的疗效，降低癌症死亡率。由于合成成本低、生物相容性和易于配制，需要在体外​​和体内进行更多研究，以便将这种新技术用于治疗人类乳腺癌。本综述中包含的调查表明，sSLN 通过克服生物屏障来递送药物，并显示出比未结合的 SLN 增强和更好的活性，这也证实了较低浓度的药物可以显示出抗乳腺癌活性。通过隐形 SLN，可以提高药物的疗效，降低癌症死亡率。由于合成成本低、生物相容性和易于配制，需要在体外​​和体内进行更多研究，以便将这种新技术用于治疗人类乳腺癌。通过隐形 SLN，可以提高药物的疗效，降低癌症死亡率。由于合成成本低、生物相容性和易于配制，需要在体外​​和体内进行更多研究，以便将这种新技术用于治疗人类乳腺癌。通过隐形 SLN，可以提高药物的疗效，降低癌症死亡率。由于合成成本低、生物相容性和易于配制，需要在体外​​和体内进行更多研究，以便将这种新技术用于治疗人类乳腺癌。